β-Adrenergic Agonists

  • Clifton T. Furukawa
Part of the Current Clinical Practice book series (CCP)


β-adrenergic agonists, and especially β2-adrenergic agonists, are generally prescribed for all asthmatics as backup medication to anti-inflammatory therapy or, in the case of exercise-induced asthma, as the primary drug. Technological advances have led to the development of increased β2-specific adrenergic agonists of longer duration of action. The effectiveness of β-adrenergic agonists in treating asthma is indisputable. However, the very effectiveness of these drugs causes problems of overuse, and consequent side effects, raising issues such as whether other drugs or other parameters should be preferentially utilized.


Adrenergic Agonist Asthma Death Injectable Route Bronchodilator Action Adrenergic Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Suggested Reading

  1. Blauw GJ, Westendorp RGJ. Asthma deaths in New Zealand: Whodunnit? Commentary. Lancet 1995; 345: 2–3.PubMedCrossRefGoogle Scholar
  2. Drotar DE, Davis EE, Cockcroft DW. Tolerance to the bronchoprotective effect of salmeterol 12 hours after starting twice-daily treatment. Ann Allergy Asthma Immunol 1997; 79: 31–34.Google Scholar
  3. Drugs for asthma Medical Letter 1995;37:1–4.Google Scholar
  4. Furukawa CT, Kemp JP, Simons FER, Tinkelman DG. The proper role of 132-adrenergic agonists in the treatment of children with asthma. Pediatrics 1992; 90: 639–640.PubMedGoogle Scholar
  5. Gibson P, Henry D, Francis L, Chuickshank D, Dupen F, Higginbotham N, et al. Association between availability of non-prescription beta 2 antagonist inhalers and undertreatment of asthma. BMJ 1993; 306: 1514–1518.PubMedCrossRefGoogle Scholar
  6. McFadden ER. Perspectives in (32-agonist therapy: Vox clamantis in deserto vel lux tenebris? J Allergy Clin Immunol 1995; 95: 641–651.PubMedCrossRefGoogle Scholar
  7. Mullen M, Mullen B, Carey M. The association between 13-agonist use and death from asthma. JAMA 1993; 270: 1842–1845.PubMedCrossRefGoogle Scholar
  8. Simons FER, Gerstner TV, Cheang MS. Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticosteroid treatment. Pediatrics 1997; 99: 655–659.PubMedCrossRefGoogle Scholar
  9. Suissa S, Ernst P, Boivin JF, Horwitz RI, Habbick B, Cockroft D, et al. A cohort analysis of excess mortality in asthma and the use of inhaled p-agonists. Am J Respir Crit Care Med 1994; 149: 604–610.PubMedCrossRefGoogle Scholar
  10. Taylor DR, Sears MR, Herbison GP, Flannery EM, Print CG, Lake DC, et al. Regular inhaled 13 agonist in asthma: Effects on exacerbations and lung function. Thorax 1993; 48: 134–138.PubMedCrossRefGoogle Scholar
  11. Taylor DR Sears MR. Regular beta-adrenergic agonists. Evidence, not reassurance, is what is needed. Chest 1994;106:552–559.Google Scholar
  12. Wahedna I, Wong CS, Wisniewski AFZ, Pavord AD, Tattersfield AE. Asthma control during and after cessation of regular beta-2 agonist treatment. Am Rev Respir Dis 1993; 148: 707–712.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2000

Authors and Affiliations

  • Clifton T. Furukawa

There are no affiliations available

Personalised recommendations